Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation

PURPOSE: Asthma is a common, chronic respiratory disorder associated with substantial societal and economic burden globally, despite the availability of different treatment modalities. GSK has developed a once-daily single-inhaler triple therapy (SITT), comprised of fluticasone furoate/umeclidinium/...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamouda, Mohamed, Farghaly, Mohamed, Al Dallal, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351593/
https://www.ncbi.nlm.nih.gov/pubmed/37465356
http://dx.doi.org/10.2147/CEOR.S407025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351593/
https://www.ncbi.nlm.nih.gov/pubmed/37465356
http://dx.doi.org/10.2147/CEOR.S407025

Ejemplares similares